Keshari Thakali
Concepts (287)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Vasoconstriction | 8 | 2009 | 55 | 1.510 |
Why?
| Obesity | 8 | 2024 | 1108 | 1.330 |
Why?
| Placenta | 3 | 2020 | 132 | 1.200 |
Why?
| Maternal Nutritional Physiological Phenomena | 4 | 2020 | 57 | 1.180 |
Why?
| Umbilical Cord | 3 | 2017 | 35 | 1.140 |
Why?
| DNA Methylation | 4 | 2020 | 550 | 1.070 |
Why?
| P-Selectin | 1 | 2024 | 32 | 0.950 |
Why?
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2024 | 32 | 0.940 |
Why?
| Platelet Activation | 1 | 2024 | 47 | 0.930 |
Why?
| Aorta, Thoracic | 8 | 2008 | 92 | 0.930 |
Why?
| Muscle, Smooth, Vascular | 8 | 2013 | 129 | 0.890 |
Why?
| Endothelin-1 | 5 | 2007 | 31 | 0.850 |
Why?
| Blood Platelets | 1 | 2024 | 249 | 0.800 |
Why?
| Hydrogen Peroxide | 3 | 2006 | 115 | 0.760 |
Why?
| Pregnancy Complications | 5 | 2020 | 382 | 0.760 |
Why?
| Venae Cavae | 4 | 2007 | 9 | 0.690 |
Why?
| Veins | 4 | 2022 | 71 | 0.680 |
Why?
| Vasodilation | 3 | 2011 | 96 | 0.670 |
Why?
| Hypertension | 6 | 2013 | 537 | 0.610 |
Why?
| Weight Gain | 3 | 2019 | 239 | 0.590 |
Why?
| Adiposity | 5 | 2024 | 133 | 0.590 |
Why?
| Calcium Channels, L-Type | 3 | 2017 | 67 | 0.590 |
Why?
| Diet | 2 | 2024 | 557 | 0.580 |
Why?
| Adipocytes, Brown | 1 | 2016 | 9 | 0.570 |
Why?
| Body Mass Index | 1 | 2020 | 656 | 0.560 |
Why?
| Thermogenesis | 1 | 2016 | 24 | 0.560 |
Why?
| Adipose Tissue, Brown | 1 | 2016 | 40 | 0.550 |
Why?
| Trophoblasts | 2 | 2015 | 29 | 0.540 |
Why?
| Oxidants | 3 | 2007 | 53 | 0.530 |
Why?
| Placentation | 1 | 2015 | 10 | 0.530 |
Why?
| Adenosine Triphosphate | 1 | 2016 | 233 | 0.520 |
Why?
| Calcium | 4 | 2017 | 400 | 0.510 |
Why?
| Rats, Sprague-Dawley | 14 | 2011 | 1586 | 0.470 |
Why?
| Transcriptome | 2 | 2015 | 320 | 0.460 |
Why?
| Pregnancy | 11 | 2024 | 2604 | 0.450 |
Why?
| Epigenesis, Genetic | 2 | 2017 | 378 | 0.430 |
Why?
| Animals | 22 | 2024 | 13246 | 0.410 |
Why?
| Intracellular Signaling Peptides and Proteins | 3 | 2011 | 143 | 0.410 |
Why?
| Insulin Resistance | 1 | 2014 | 262 | 0.400 |
Why?
| Rats | 14 | 2011 | 3299 | 0.390 |
Why?
| Receptors, Endothelin | 2 | 2008 | 7 | 0.370 |
Why?
| Gene Expression Regulation | 2 | 2017 | 979 | 0.360 |
Why?
| Male | 23 | 2024 | 25399 | 0.360 |
Why?
| Nifedipine | 1 | 2009 | 25 | 0.350 |
Why?
| Inflammation | 1 | 2014 | 604 | 0.350 |
Why?
| Drug Resistance | 1 | 2009 | 64 | 0.340 |
Why?
| Calcium Channel Blockers | 1 | 2009 | 63 | 0.340 |
Why?
| Vasodilator Agents | 1 | 2009 | 98 | 0.330 |
Why?
| Vena Cava, Inferior | 2 | 2007 | 79 | 0.320 |
Why?
| Receptor, Endothelin B | 1 | 2008 | 2 | 0.310 |
Why?
| Muscle Contraction | 4 | 2017 | 106 | 0.310 |
Why?
| Blotting, Western | 5 | 2014 | 601 | 0.290 |
Why?
| Prostaglandin-Endoperoxide Synthases | 1 | 2006 | 26 | 0.280 |
Why?
| Infant, Newborn | 6 | 2020 | 2766 | 0.280 |
Why?
| Extracellular Signal-Regulated MAP Kinases | 1 | 2006 | 83 | 0.270 |
Why?
| Cohort Studies | 3 | 2020 | 1422 | 0.270 |
Why?
| src-Family Kinases | 1 | 2006 | 51 | 0.270 |
Why?
| p38 Mitogen-Activated Protein Kinases | 1 | 2006 | 96 | 0.270 |
Why?
| Diet, High-Fat | 2 | 2018 | 220 | 0.260 |
Why?
| Nitric Oxide | 1 | 2006 | 254 | 0.240 |
Why?
| Platelet Glycoprotein GPIb-IX Complex | 1 | 2024 | 49 | 0.240 |
Why?
| Female | 14 | 2024 | 26635 | 0.230 |
Why?
| Early Growth Response Protein 1 | 2 | 2014 | 35 | 0.220 |
Why?
| Venous Valves | 1 | 2022 | 1 | 0.210 |
Why?
| Mice, Inbred C57BL | 3 | 2024 | 1819 | 0.200 |
Why?
| Bioprosthesis | 1 | 2022 | 35 | 0.200 |
Why?
| Mothers | 2 | 2024 | 254 | 0.190 |
Why?
| Mesenteric Arteries | 2 | 2012 | 45 | 0.190 |
Why?
| Humans | 16 | 2024 | 50208 | 0.190 |
Why?
| CpG Islands | 1 | 2020 | 107 | 0.170 |
Why?
| Antioxidants | 2 | 2015 | 241 | 0.170 |
Why?
| Regression Analysis | 2 | 2017 | 395 | 0.160 |
Why?
| Angiotensin II | 2 | 2012 | 157 | 0.160 |
Why?
| Mice | 4 | 2024 | 5759 | 0.160 |
Why?
| Epigenomics | 2 | 2016 | 68 | 0.160 |
Why?
| Myocytes, Smooth Muscle | 3 | 2017 | 86 | 0.160 |
Why?
| Adult | 6 | 2024 | 13324 | 0.160 |
Why?
| Maternal Exposure | 1 | 2018 | 86 | 0.150 |
Why?
| Prenatal Exposure Delayed Effects | 2 | 2017 | 185 | 0.150 |
Why?
| Escherichia coli Proteins | 3 | 2015 | 56 | 0.150 |
Why?
| Insulin-Like Growth Factor Binding Protein 1 | 1 | 2017 | 8 | 0.150 |
Why?
| Overweight | 1 | 2020 | 217 | 0.150 |
Why?
| Body Composition | 1 | 2019 | 319 | 0.150 |
Why?
| AMP-Activated Protein Kinases | 1 | 2017 | 29 | 0.150 |
Why?
| Fatty Liver | 1 | 2018 | 127 | 0.150 |
Why?
| Reactive Oxygen Species | 3 | 2015 | 408 | 0.140 |
Why?
| Hydroxybenzoates | 2 | 2015 | 18 | 0.140 |
Why?
| Parents | 1 | 2019 | 315 | 0.140 |
Why?
| Lipid Metabolism | 2 | 2018 | 175 | 0.140 |
Why?
| Real-Time Polymerase Chain Reaction | 2 | 2014 | 181 | 0.140 |
Why?
| Vena Cava, Superior | 2 | 2008 | 22 | 0.130 |
Why?
| rho-Associated Kinases | 2 | 2006 | 20 | 0.130 |
Why?
| Arteries | 2 | 2007 | 92 | 0.130 |
Why?
| Estradiol | 1 | 2017 | 225 | 0.130 |
Why?
| Fetal Development | 1 | 2016 | 59 | 0.130 |
Why?
| Cell Fusion | 1 | 2015 | 17 | 0.130 |
Why?
| Coronary Vessels | 1 | 2017 | 157 | 0.130 |
Why?
| Enzyme Inhibitors | 2 | 2009 | 386 | 0.130 |
Why?
| Gene Expression Profiling | 3 | 2017 | 1037 | 0.130 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2014 | 595 | 0.130 |
Why?
| Chlorogenic Acid | 1 | 2015 | 4 | 0.130 |
Why?
| Proteins | 1 | 2017 | 345 | 0.120 |
Why?
| Disease Models, Animal | 2 | 2017 | 1458 | 0.120 |
Why?
| Proto-Oncogene Proteins c-fos | 1 | 2014 | 62 | 0.120 |
Why?
| Microarray Analysis | 1 | 2014 | 73 | 0.120 |
Why?
| Adipogenesis | 1 | 2014 | 50 | 0.120 |
Why?
| Fruit | 1 | 2015 | 112 | 0.120 |
Why?
| DNA Primers | 1 | 2014 | 207 | 0.120 |
Why?
| Anthropometry | 1 | 2014 | 92 | 0.120 |
Why?
| Cell Adhesion Molecules | 1 | 2014 | 89 | 0.110 |
Why?
| Human Umbilical Vein Endothelial Cells | 1 | 2014 | 90 | 0.110 |
Why?
| Anti-Inflammatory Agents | 1 | 2015 | 160 | 0.110 |
Why?
| Histones | 1 | 2015 | 313 | 0.110 |
Why?
| Patch-Clamp Techniques | 2 | 2011 | 124 | 0.110 |
Why?
| Membrane Potentials | 2 | 2011 | 117 | 0.110 |
Why?
| Oxidoreductases | 2 | 2004 | 60 | 0.110 |
Why?
| Blood Pressure | 4 | 2012 | 524 | 0.110 |
Why?
| Potassium Channels | 1 | 2013 | 32 | 0.110 |
Why?
| Calcium Channels | 1 | 2013 | 46 | 0.110 |
Why?
| Leptin | 1 | 2014 | 140 | 0.110 |
Why?
| Potassium Chloride | 2 | 2009 | 20 | 0.110 |
Why?
| Analysis of Variance | 1 | 2014 | 564 | 0.110 |
Why?
| Escherichia coli | 2 | 2004 | 186 | 0.100 |
Why?
| Oxidative Stress | 2 | 2007 | 771 | 0.100 |
Why?
| Antihypertensive Agents | 1 | 2013 | 121 | 0.100 |
Why?
| Post-Synaptic Density | 1 | 2011 | 4 | 0.100 |
Why?
| Insulin | 1 | 2014 | 456 | 0.100 |
Why?
| Shaker Superfamily of Potassium Channels | 1 | 2011 | 10 | 0.100 |
Why?
| Vasoconstrictor Agents | 2 | 2009 | 84 | 0.100 |
Why?
| Immunohistochemistry | 3 | 2011 | 978 | 0.100 |
Why?
| Cell Differentiation | 1 | 2014 | 650 | 0.100 |
Why?
| Cerebral Arteries | 1 | 2011 | 40 | 0.100 |
Why?
| Renal Circulation | 1 | 2011 | 59 | 0.090 |
Why?
| Up-Regulation | 1 | 2012 | 453 | 0.090 |
Why?
| Potassium Channel Blockers | 2 | 2011 | 16 | 0.090 |
Why?
| Young Adult | 1 | 2020 | 3981 | 0.090 |
Why?
| Matrix Metalloproteinases | 2 | 2007 | 48 | 0.090 |
Why?
| Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2009 | 8 | 0.090 |
Why?
| Mesenteric Veins | 1 | 2009 | 13 | 0.090 |
Why?
| Chelating Agents | 1 | 2009 | 27 | 0.090 |
Why?
| Hemodynamics | 1 | 2011 | 263 | 0.090 |
Why?
| Desoxycorticosterone | 2 | 2007 | 6 | 0.090 |
Why?
| Adaptation, Physiological | 2 | 2007 | 91 | 0.090 |
Why?
| Sodium Chloride | 2 | 2007 | 58 | 0.080 |
Why?
| Membrane Proteins | 1 | 2011 | 353 | 0.080 |
Why?
| Child, Preschool | 3 | 2024 | 3883 | 0.080 |
Why?
| Sepsis | 1 | 2011 | 221 | 0.080 |
Why?
| Animals, Genetically Modified | 1 | 2008 | 49 | 0.080 |
Why?
| Tachyphylaxis | 1 | 2007 | 2 | 0.070 |
Why?
| beta-Cyclodextrins | 1 | 2007 | 16 | 0.070 |
Why?
| Acute Kidney Injury | 1 | 2011 | 285 | 0.070 |
Why?
| Norepinephrine | 2 | 2007 | 113 | 0.070 |
Why?
| Data Interpretation, Statistical | 1 | 2008 | 157 | 0.070 |
Why?
| Myosin Heavy Chains | 1 | 2007 | 20 | 0.070 |
Why?
| Thromboxane A2 | 1 | 2006 | 16 | 0.070 |
Why?
| Spin Labels | 1 | 2006 | 5 | 0.070 |
Why?
| Nitroarginine | 1 | 2006 | 8 | 0.070 |
Why?
| Ganglia, Sympathetic | 1 | 2006 | 3 | 0.070 |
Why?
| Cyclic N-Oxides | 1 | 2006 | 12 | 0.070 |
Why?
| Peptide Fragments | 1 | 2007 | 213 | 0.070 |
Why?
| Superoxides | 1 | 2006 | 46 | 0.070 |
Why?
| Dose-Response Relationship, Drug | 1 | 2009 | 1378 | 0.070 |
Why?
| Extracellular Fluid | 1 | 2006 | 14 | 0.070 |
Why?
| Ouabain | 1 | 2006 | 28 | 0.070 |
Why?
| Nitric Oxide Synthase | 1 | 2006 | 75 | 0.070 |
Why?
| Copper | 2 | 2004 | 43 | 0.060 |
Why?
| Drug Synergism | 1 | 2006 | 151 | 0.060 |
Why?
| Sodium-Potassium-Exchanging ATPase | 1 | 2006 | 61 | 0.060 |
Why?
| Myosin-Light-Chain Phosphatase | 1 | 2005 | 3 | 0.060 |
Why?
| rhoA GTP-Binding Protein | 1 | 2005 | 7 | 0.060 |
Why?
| Siderophores | 1 | 2004 | 6 | 0.060 |
Why?
| Fathers | 1 | 2024 | 24 | 0.060 |
Why?
| Thoracic Arteries | 1 | 2004 | 1 | 0.060 |
Why?
| Norfenfluramine | 1 | 2004 | 2 | 0.060 |
Why?
| Fenfluramine | 1 | 2004 | 7 | 0.060 |
Why?
| Atherosclerosis | 1 | 2007 | 214 | 0.060 |
Why?
| Phosphorylation | 1 | 2005 | 534 | 0.060 |
Why?
| Interleukin-6 | 2 | 2015 | 265 | 0.050 |
Why?
| Glutaral | 1 | 2022 | 2 | 0.050 |
Why?
| Tumor Necrosis Factor-alpha | 2 | 2015 | 388 | 0.050 |
Why?
| Longitudinal Studies | 1 | 2024 | 695 | 0.050 |
Why?
| Benchmarking | 1 | 2022 | 61 | 0.050 |
Why?
| Temperature | 1 | 2022 | 168 | 0.050 |
Why?
| Exercise | 1 | 2024 | 503 | 0.040 |
Why?
| Signal Transduction | 1 | 2006 | 1622 | 0.040 |
Why?
| Infant | 2 | 2020 | 3563 | 0.040 |
Why?
| Insulin-Like Growth Factor I | 1 | 2019 | 138 | 0.040 |
Why?
| Cardiovascular Diseases | 1 | 2024 | 443 | 0.040 |
Why?
| Biodiversity | 1 | 2018 | 38 | 0.040 |
Why?
| Metagenome | 1 | 2018 | 40 | 0.040 |
Why?
| Metagenomics | 1 | 2018 | 40 | 0.040 |
Why?
| Metabolic Networks and Pathways | 1 | 2018 | 89 | 0.040 |
Why?
| Bile Acids and Salts | 1 | 2018 | 76 | 0.040 |
Why?
| Gestational Age | 1 | 2019 | 418 | 0.040 |
Why?
| Phylogeny | 1 | 2018 | 234 | 0.040 |
Why?
| RNA, Messenger | 2 | 2014 | 1108 | 0.040 |
Why?
| Overnutrition | 1 | 2017 | 10 | 0.040 |
Why?
| Estrogen Receptor beta | 1 | 2017 | 54 | 0.040 |
Why?
| Choline Deficiency | 1 | 2017 | 23 | 0.040 |
Why?
| Sex Characteristics | 1 | 2018 | 191 | 0.040 |
Why?
| Choline | 1 | 2017 | 61 | 0.040 |
Why?
| Estrogen Receptor alpha | 1 | 2017 | 89 | 0.040 |
Why?
| Swine | 1 | 2017 | 396 | 0.030 |
Why?
| Methionine | 1 | 2017 | 135 | 0.030 |
Why?
| Risk Factors | 1 | 2024 | 3629 | 0.030 |
Why?
| Anisotropy | 1 | 2015 | 63 | 0.030 |
Why?
| Erythrocytes | 1 | 2015 | 83 | 0.030 |
Why?
| Diffusion Tensor Imaging | 1 | 2015 | 91 | 0.030 |
Why?
| Cell Culture Techniques | 1 | 2015 | 99 | 0.030 |
Why?
| Culture Media | 1 | 2014 | 93 | 0.030 |
Why?
| Cells, Cultured | 1 | 2017 | 1581 | 0.030 |
Why?
| Chromatography, High Pressure Liquid | 1 | 2015 | 327 | 0.030 |
Why?
| Activating Transcription Factor 3 | 1 | 2013 | 8 | 0.030 |
Why?
| NF-kappa B | 1 | 2015 | 315 | 0.030 |
Why?
| Palmitates | 1 | 2013 | 29 | 0.030 |
Why?
| Child Development | 1 | 2015 | 191 | 0.030 |
Why?
| Ion Channel Gating | 1 | 2013 | 39 | 0.030 |
Why?
| Interleukin-8 | 1 | 2013 | 86 | 0.030 |
Why?
| Genotype | 1 | 2014 | 534 | 0.030 |
Why?
| Protein Subunits | 1 | 2013 | 77 | 0.030 |
Why?
| Serum Response Factor | 1 | 2013 | 42 | 0.030 |
Why?
| MAP Kinase Signaling System | 1 | 2013 | 118 | 0.030 |
Why?
| Molecular Targeted Therapy | 1 | 2013 | 121 | 0.030 |
Why?
| Spider Venoms | 1 | 2011 | 6 | 0.020 |
Why?
| Oligonucleotides, Antisense | 1 | 2011 | 28 | 0.020 |
Why?
| Gene Knockdown Techniques | 1 | 2011 | 106 | 0.020 |
Why?
| Phenotype | 1 | 2014 | 733 | 0.020 |
Why?
| Ligation | 1 | 2011 | 59 | 0.020 |
Why?
| Capillary Permeability | 1 | 2011 | 35 | 0.020 |
Why?
| Telemetry | 1 | 2011 | 32 | 0.020 |
Why?
| Liver | 1 | 2017 | 1116 | 0.020 |
Why?
| Peritonitis | 1 | 2011 | 27 | 0.020 |
Why?
| Multiple Organ Failure | 1 | 2011 | 47 | 0.020 |
Why?
| Microcirculation | 1 | 2011 | 71 | 0.020 |
Why?
| Cecum | 1 | 2011 | 63 | 0.020 |
Why?
| Blood Flow Velocity | 1 | 2011 | 101 | 0.020 |
Why?
| Hypothermia | 1 | 2011 | 35 | 0.020 |
Why?
| Fluid Therapy | 1 | 2011 | 75 | 0.020 |
Why?
| Cell Line | 1 | 2013 | 1021 | 0.020 |
Why?
| Animals, Newborn | 1 | 2011 | 368 | 0.020 |
Why?
| Chymases | 1 | 2007 | 3 | 0.020 |
Why?
| Glycopeptides | 1 | 2007 | 10 | 0.020 |
Why?
| Organophosphonates | 1 | 2007 | 7 | 0.020 |
Why?
| Isometric Contraction | 1 | 2007 | 21 | 0.020 |
Why?
| Aspartic Acid Endopeptidases | 1 | 2007 | 16 | 0.020 |
Why?
| Minocycline | 1 | 2007 | 15 | 0.020 |
Why?
| Dipeptides | 1 | 2007 | 22 | 0.020 |
Why?
| Caveolin 1 | 1 | 2007 | 21 | 0.020 |
Why?
| Immunoprecipitation | 1 | 2007 | 59 | 0.020 |
Why?
| Microscopy, Electron, Transmission | 1 | 2007 | 75 | 0.020 |
Why?
| Tetrazoles | 1 | 2007 | 40 | 0.020 |
Why?
| Protease Inhibitors | 1 | 2007 | 58 | 0.020 |
Why?
| Metalloendopeptidases | 1 | 2007 | 69 | 0.020 |
Why?
| Receptor, Angiotensin, Type 1 | 1 | 2007 | 57 | 0.020 |
Why?
| Cell Size | 1 | 2007 | 45 | 0.020 |
Why?
| Brain | 1 | 2015 | 1328 | 0.020 |
Why?
| Kidney | 1 | 2011 | 672 | 0.020 |
Why?
| Enterobactin | 1 | 2004 | 1 | 0.020 |
Why?
| Artificial Gene Fusion | 1 | 2004 | 7 | 0.020 |
Why?
| beta-Galactosidase | 1 | 2004 | 35 | 0.020 |
Why?
| Genes, Bacterial | 1 | 2004 | 64 | 0.020 |
Why?
| Gene Expression | 1 | 2007 | 609 | 0.010 |
Why?
| Genes, Reporter | 1 | 2004 | 88 | 0.010 |
Why?
| Sympathectomy | 1 | 2004 | 2 | 0.010 |
Why?
| Prazosin | 1 | 2004 | 10 | 0.010 |
Why?
| Ergolines | 1 | 2004 | 3 | 0.010 |
Why?
| Ketanserin | 1 | 2004 | 9 | 0.010 |
Why?
| Serotonin 5-HT2 Receptor Antagonists | 1 | 2004 | 9 | 0.010 |
Why?
| Receptors, Adrenergic, alpha | 1 | 2004 | 15 | 0.010 |
Why?
| Drug Resistance, Bacterial | 1 | 2004 | 71 | 0.010 |
Why?
| Receptor, Serotonin, 5-HT2C | 1 | 2004 | 6 | 0.010 |
Why?
| Sympathetic Nervous System | 1 | 2004 | 19 | 0.010 |
Why?
| Serotonin Antagonists | 1 | 2004 | 34 | 0.010 |
Why?
| Receptor, Serotonin, 5-HT2A | 1 | 2004 | 12 | 0.010 |
Why?
| Gene Deletion | 1 | 2004 | 270 | 0.010 |
Why?
| Oxidation-Reduction | 1 | 2004 | 320 | 0.010 |
Why?
| Repressor Proteins | 1 | 2004 | 153 | 0.010 |
Why?
| Gene Expression Regulation, Bacterial | 1 | 2004 | 191 | 0.010 |
Why?
| Aorta | 1 | 2004 | 162 | 0.010 |
Why?
| Electron Transport | 1 | 2002 | 25 | 0.010 |
Why?
| Crystallography, X-Ray | 1 | 2002 | 148 | 0.010 |
Why?
| Protein Structure, Tertiary | 1 | 2002 | 253 | 0.010 |
Why?
| Bacterial Proteins | 1 | 2004 | 376 | 0.010 |
Why?
| Homeostasis | 1 | 2002 | 201 | 0.010 |
Why?
| Models, Molecular | 1 | 2002 | 341 | 0.010 |
Why?
| Kinetics | 1 | 2002 | 631 | 0.010 |
Why?
| Anti-Bacterial Agents | 1 | 2004 | 747 | 0.010 |
Why?
|
|
Thakali's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|